Aurobindo Pharma's US subsidiary has received U.S. FTC approval for its $250 million acquisition of Lannett Company. The deal, expected to close by June 2026, adds significant U.S. manufacturing capacity and is projected to boost earnings per share.
Aurobindo Pharma Gets FTC Green Light for Lannett Acquisition
$250 Million Deal Secures U.S. Manufacturing and EPS Accretion
Reader Takeaway: FTC approval is a key step; expect EPS boost and expanded US manufacturing capabilities.
What just happened
Aurobindo Pharma Limited, via its subsidiary Aurobindo Pharma USA, Inc., has secured approval from the U.S. Federal Trade Commission (FTC) to proceed with its $250 million cash-free, debt-free acquisition of Lannett Company, LLC. This regulatory clearance is a significant milestone towards the deal's closure, anticipated before the end of June 2026.
Why this matters
The acquisition is strategically designed to bolster Aurobindo's presence in the North American pharmaceutical market. It brings substantial manufacturing capacity, adding approximately 4 billion doses annually from Lannett's Seymour, Indiana facility. Management expects the deal to be immediately accretive to the Aurobindo Group's earnings per share (EPS), signalling a positive financial impact.
The backstory
Aurobindo Pharma has been expanding its global footprint, with a particular focus on strengthening its U.S. operations. Lannett Company, a provider of generic pharmaceuticals, has faced its own set of market dynamics. This acquisition represents Aurobindo's strategic move to consolidate and enhance its capabilities in a key market.
What changes now
With FTC approval in hand, the path is clearer for Aurobindo Pharma to finalize the $250 million acquisition. The company will now focus on integrating Lannett's operations, including its specialized non-opioid controlled substances portfolio and manufacturing site. Shareholders can anticipate updates on synergy realization and actual EPS impact post-closure.
Risks to watch
While FTC approval removes a major hurdle, potential risks include integration challenges, unexpected costs, and the actual realization of projected operational synergies and EPS accretion. Market conditions and regulatory scrutiny on pharmaceutical deals remain a constant backdrop.
Peer comparison
While specific direct acquisitions might vary, pharmaceutical companies frequently engage in M&A to gain market share, access new product lines, or enhance manufacturing capabilities. Competitors also focus on expanding their generic drug portfolios and U.S.-based production to ensure supply chain resilience.
Context metrics (time-bound)
The transaction value is set at $250 million on a cash-free, debt-free basis. Regulatory approval was received from the FTC. The expected closure date is before the end of June 2026. The acquired manufacturing capacity is approximately 4 billion doses annually.
What to track next
Investors should monitor the final closing of the transaction and subsequent financial reports for details on the integration progress. Key metrics to watch will be the realization of cost and SG&A synergies, and the confirmed impact on Aurobindo's consolidated EPS.